SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid TumorsNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- SHY Therapeutics (“SHY” or “the Company”), a clinical-stage biotechnology company developing small molecules that non-covalently target ATPases and GTPases and modulate their activity, today announced that the first patient has been dosed in Luca-1, the Company's first-in-human Phase 1 clinical trial evaluating SHY-ONC6, an investigational, novel and potentially first-in-class oral proteasome inhibitor for patients with advanced solid tumors. The Company expects initial Phase 1 data in 2027.
